Soliton
7
0
0
7
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 45/100
0.0%
0 terminated/withdrawn out of 7 trials
100.0%
+13.5% vs industry average
0%
0 trials in Phase 3/4
0%
0 of 7 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (7)
Treatment of Fibrotic Scars With Rapid Acoustic Pulse (RAP) Device
Role: lead
Study to Evaluate the Safety and Effectiveness of the RAP Device for the Improvement in the Appearance of Cellulite
Role: lead
Soliton Planar Acoustic Wave Device System for Dermal Tattoo Clearing Human Trial Protocol
Role: lead
Proof of Concept (POC) Study of the Soliton Rapid Acoustic (RAP) for the Treatment of Cellulite
Role: lead
Proof of Concept (POC) Study of the Soliton's Acoustic Scar Reduction (ASR) Treatment for the Treatment of Keloid Scar
Role: lead
Study of the Soliton Rapid Acoustic Pulse (RAP) Device for the Treatment of Cellulite
Role: lead
Soliton Planar Acoustic Wave Device System for Dermal Clearing Human Trial Protocol
Role: lead
All 7 trials loaded